Recent regulatory filings have detailed specific equity transactions by Annette F. Favorite, who serves as Senior Vice President and Chief Human Resources Officer for West Pharmaceutical Services Inc (NYSE:WST). On April 27, 2026, Ms. Favorite engaged in a dual-step transaction involving the exercise of stock options followed by a sale of common stock.
Transaction Details
The filing indicates that Ms. Favorite first acquired 2,817 shares of West Pharmaceutical common stock through the exercise of stock options. This acquisition was conducted at an exercise price of $83.47 per share, representing a total cost of approximately $235,134. These specific options originated from an award granted on February 21, 2017, which was structured to vest in four equal annual installments starting on February 21, 2018.
Immediately following this acquisition, Ms. Favorite sold the same amount of 2,817 shares. The sale was executed at a weighted average price of $305.2018 per share, resulting in total proceeds of roughly $859,753. Following these activities, her direct holdings in West Pharmaceutical common stock stand at 16,828.4906 shares. She also maintains an indirect holding of 4,966.617 shares through a Non-Qualified Deferred Compensation Plan and holds an additional 5,635 stock options.
Financial Context and Market Performance
The timing of these transactions coincides with a period of high valuation for the medical device company. Currently, the stock is trading at levels exceeding its InvestingPro Fair Value, which suggests potential overvaluation at current market prices. Despite this, West Pharmaceutical has demonstrated robust momentum, delivering a 37% return over the last year.
The company's recent Q1 2026 financial performance was notably strong, with results that exceeded market expectations on both the top and bottom lines. Adjusted earnings per share (EPS) were reported at $2.13, surpassing the anticipated $1.68. Additionally, revenue for the quarter reached $845 million, which was higher than the forecasted $780.65 million.
Analyst Outlook
In response to these financial results, several investment firms have revised their price targets upward. The following adjustments were noted:
- Evercore ISI: Raised its target to $390, pointing toward strong financial results and future valuation projections.
- TD Cowen: Established a new target of $365, noting an acceleration in the transition toward high-value products.
- BofA Securities: Increased its target to $350, citing improved execution and first-quarter performance.
- Barclays: Lifted its target to $310, based on growth across various business segments and a continuing recovery in demand.
These revisions reflect a generally optimistic sentiment among analysts regarding the company's operational trajectory and future value prospects.